84 related articles for article (PubMed ID: 18721824)
1. The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances.
Zawacka-Pankau J; Krachulec J; Grulkowski I; Bielawski KP; Selivanova G
Toxicol Appl Pharmacol; 2008 Nov; 232(3):487-97. PubMed ID: 18721824
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy sensitivity is not altered in human tumor cells after abrogation of p53 function.
Fisher AM; Ferrario A; Rucker N; Zhang S; Gomer CJ
Cancer Res; 1999 Jan; 59(2):331-5. PubMed ID: 9927042
[TBL] [Abstract][Full Text] [Related]
3. p53 family members - important messengers in cell death signaling in photodynamic therapy of cancer?
Acedo P; Zawacka-Pankau J
Photochem Photobiol Sci; 2015 Aug; 14(8):1390-6. PubMed ID: 26202022
[TBL] [Abstract][Full Text] [Related]
4. Wild-type p53 gene transfer into mutated p53 HT29 cells improves sensitivity to photodynamic therapy via induction of apoptosis.
Barberi-Heyob M; Védrine PO; Merlin JL; Millon R; Abecassis J; Poupon MF; Guillemin F
Int J Oncol; 2004 Apr; 24(4):951-8. PubMed ID: 15010835
[TBL] [Abstract][Full Text] [Related]
5. Clinical and experimental evidence of Bcl-2 involvement in the response to photodynamic therapy.
Koukourakis MI; Corti L; Skarlatos J; Giatromanolaki A; Krammer B; Blandamura S; Piazza M; Verwanger T; Schnitzhofer G; Kostandelos J; Beroukas K
Anticancer Res; 2001; 21(1B):663-8. PubMed ID: 11299823
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated p53 treatment enhances photodynamic antitumor response.
Lim DS; Bae SM; Kwak SY; Park EK; Kim JK; Han SJ; Oh CH; Lee CH; Lee WY; Ahn WS
Hum Gene Ther; 2006 Mar; 17(3):347-52. PubMed ID: 16544983
[TBL] [Abstract][Full Text] [Related]
7. The role of apoptosis in response to photodynamic therapy: what, where, why, and how.
Oleinick NL; Morris RL; Belichenko I
Photochem Photobiol Sci; 2002 Jan; 1(1):1-21. PubMed ID: 12659143
[TBL] [Abstract][Full Text] [Related]
8. New insights into the mechanisms for photodynamic therapy-induced cancer cell death.
Yoo JO; Ha KS
Int Rev Cell Mol Biol; 2012; 295():139-74. PubMed ID: 22449489
[TBL] [Abstract][Full Text] [Related]
9. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation.
Bergamaschi D; Samuels Y; Zhong S; Lu X
Oncogene; 2005 May; 24(23):3836-41. PubMed ID: 15782125
[TBL] [Abstract][Full Text] [Related]
10. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells.
Shen XY; Zacal N; Singh G; Rainbow AJ
Photochem Photobiol; 2005; 81(2):306-13. PubMed ID: 15560738
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy resistant human colon carcinoma HT29 cells show cross-resistance to UVA but not UVC light.
Zacal N; Rainbow AJ
Photochem Photobiol; 2007; 83(3):730-7. PubMed ID: 17576382
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial reactive oxygen species and nitric oxide-mediated cancer cell apoptosis in 2-butylamino-2-demethoxyhypocrellin B photodynamic treatment.
Lu Z; Tao Y; Zhou Z; Zhang J; Li C; Ou L; Zhao B
Free Radic Biol Med; 2006 Nov; 41(10):1590-605. PubMed ID: 17045927
[TBL] [Abstract][Full Text] [Related]
13. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
14. Activation and activities of the p53 tumour suppressor protein.
Bálint E E; Vousden KH
Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
[TBL] [Abstract][Full Text] [Related]
15. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
16. Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells.
Ali SM; Olivo M
Int J Oncol; 2002 Sep; 21(3):531-40. PubMed ID: 12168096
[TBL] [Abstract][Full Text] [Related]
17. Strategies for manipulating the p53 pathway in the treatment of human cancer.
Hupp TR; Lane DP; Ball KL
Biochem J; 2000 Nov; 352 Pt 1(Pt 1):1-17. PubMed ID: 11062053
[TBL] [Abstract][Full Text] [Related]
18. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
19. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
